{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:38:23Z","timestamp":1762144703663,"version":"build-2065373602"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T00:00:00Z","timestamp":1267488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Bruegel Study Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2010,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's optimal dose (9\u201345 mg\/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks. Concomitant anti\u2010Parkinson treatment was not permitted. In the primary analysis, Unified PD Rating Scale (UPDRS)\u2010Motor score was improved in pardoprunox\u2010treated patients (overall mean dose 23.8 mg\/d; \u22127.3 points), as compared with placebo (\u22123.0 points; <jats:italic>P<\/jats:italic> = 0.0001), from baseline to end point. At end point, there were more responders (\u226530% reduction in UPDRS\u2010Motor score) in the pardoprunox group (50.7%) than in the placebo group (15.7%; <jats:italic>P<\/jats:italic> &lt; 0.0001). In other secondary analyses, UPDRS\u2010activities of daily living (ADL) and \u2010ADL+Motor scores were also significantly more improved in the pardoprunox group. Nausea was reported by 32 of 68 (47.1%) pardoprunox\u2010treated patients (vs. 3\/70, 4.3%, placebo\u2010treated patients), with dizziness, somnolence, headache, and asthenia also reported by \u226510 patients. In this exploratory proof\u2010of\u2010concept study, pardoprunox significantly improved motor function in patients with early PD. The efficacy and safety profile of pardoprunox justifies its further investigation in PD. \u00a9 2010 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.22948","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T16:56:26Z","timestamp":1267548986000},"page":"738-746","source":"Crossref","is-referenced-by-count":29,"title":["Double\u2010blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease"],"prefix":"10.1002","volume":"25","author":[{"given":"Juliana","family":"Bronzova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad","family":"Theeuwes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge V.","family":"van de Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guus","family":"van Scharrenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Bruegel Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,26]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00029-X"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00030-6"},{"key":"e_1_2_7_4_2","first-page":"51","volume-title":"Parkinson's disease (Solvay pharmaceutical conferences)","author":"McCreary AC","year":"2002"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2033-1"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.4.723"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.5.863"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090512"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199110000-00010"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20330"},{"issue":"10","key":"e_1_2_7_11_2","first-page":"P16","article-title":"Full (ropinirole) and partial (SLV308) dopamine agonists and the relationship to dyskinesia priming in MPTP\u2010treated marmosets","volume":"20","author":"Johnston L","year":"2005","journal-title":"Mov Disord"},{"key":"e_1_2_7_12_2","first-page":"165","article-title":"Parkinson's Disease Society Brain Bank, London: overview and research","volume":"39","author":"Daniel SE","year":"1993","journal-title":"J Neural Transm Suppl"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_7_14_2","series-title":"Recent developments in Parkinson's disease","first-page":"153","author":"Fahn S","year":"1987"},{"key":"e_1_2_7_15_2","first-page":"217","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"volume-title":"Third symposium of Parkinson's disease","year":"1969","author":"Schwab RS","key":"e_1_2_7_16_2"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.suppl_1.S1"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.6.1241"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2001.026.02.608830"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70521-X"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10394"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22022"},{"issue":"5","key":"e_1_2_7_24_2","first-page":"S120","article-title":"A study on dopamine D2 receptor occupancy after multiple oral administration of SLV 308 to healthy male volunteers by means of positron emission topography using 11C\u2010raclopride","volume":"17","author":"deVries MH","year":"2002","journal-title":"Mov Disord"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410310209"},{"key":"e_1_2_7_26_2","first-page":"133","article-title":"Tandospirone citrate, a selective 5\u2010HT1A agonist, alleviates L\u2010DOPA\u2010induced dyskinesia in patients with Parkinson's disease","volume":"54","author":"Kannari K","year":"2002","journal-title":"No To Shinkei"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20370"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm082"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.05.030"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.393"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21122"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.5.676"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115040-00002"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7352.1483"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22948","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:27:38Z","timestamp":1760970458000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,26]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,4,30]]}},"alternative-id":["10.1002\/mds.22948"],"URL":"https:\/\/doi.org\/10.1002\/mds.22948","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2010,4,26]]}}}